ECONOMY: Campaign Touts Region’s Prowess To Drive Medical Visits
For visitors, San Diego offers much more than beaches, craft beer and convention space.
BIOTECH: Unifying Operations Seen as Plus; Possible IPO Coming
Ra Medical Systems has outgrown its digs once again. Next month, the Carlsbad medical device company is moving to a bigger space to meet increased demand, the fifth time it has done so since forming in 2002. Its new headquarters — down the street from its current spot — will house R&D, production, sales, marketing and administrative functions in a 32,000-square-foot building.
San Diego-based Batu Biologics has received approval from the FDA to proceed with human testing of its cancer immunotherapy.
Klotho Therapeutics (KTI) raised $10 million in a Series A round from Thynk Capital, whose founder, Jim Plante, is also the founder and CEO of KTI.
San Diego’s AMN Healthcare, the U.S.’s largest health care and nurse staffing company, has reported year-over-year revenue growth in its third quarter.
Two San Diego biotechs have entered into a research collaboration and licensing agreement to develop vaccines and therapeutics for both human and animal health.
A new $244,000 grant will fund palliative care education for qualified Medi-Cal providers at the California State University Institute for Palliative Care in San Marcos.
HEALTH: Move Expected to Greatly Advance Timelines
San Diego drugmaker Tocagen accelerated its gene cancer therapy into a pivotal Phase 3 trial, which the company estimates will shave off as many as three years from the drug’s development and the U.S. Food and Drug Administration regulatory process.
BIOTECH: System Puts Patient In Active Role, Uses Gamification
Two executives of San Diego companies are pooling their areas of expertise into a health record platform built on blockchain technology.
BIOTECH: Co. Amasses Data, Turning It Into Actionable Information
ResMed earlier this year hit a milestone, amassing data on 1 billion nights of sleep.
San Diego drugmaker Ignyta Inc. is piggybacking off recent positive press by raising $160 million in a new stock offering. The fresh infusion of cash will go toward developing the company’s cancer drug.
DexCom posted third quarter revenue of $184.6 million, a 24 percent year-over-year increase.
SoulCycle, an indoor cycling and lifestyle company, plans to open a studio at Westfield UTC mall in spring 2018.
Impact Biomedicines in San Diego locked down a funding package worth up $90 million to advance the development and commercialization of a bone marrow and cancer drug.
Carlsbad-based Alphatec in preliminary quarter three results reported revenue of $22.8 to $23.1 million.